ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 59 filers reported holding ALPINE IMMUNE SCIENCES INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $218,088 | -53.7% | 19,047 | -58.5% | 0.00% | – |
| Q2 2023 | $471,338 | +663.8% | 45,850 | +473.6% | 0.00% | – |
| Q1 2023 | $61,706 | +268.9% | 7,993 | +251.2% | 0.00% | – |
| Q4 2022 | $16,729 | +67.3% | 2,276 | +89.7% | 0.00% | – |
| Q2 2022 | $10,000 | -54.5% | 1,200 | -49.3% | 0.00% | – |
| Q1 2022 | $22,000 | -68.6% | 2,369 | -52.6% | 0.00% | – |
| Q4 2021 | $70,000 | +483.3% | 4,996 | +337.5% | 0.00% | – |
| Q3 2021 | $12,000 | +71.4% | 1,142 | +65.7% | 0.00% | – |
| Q1 2021 | $7,000 | -41.7% | 689 | -50.9% | 0.00% | – |
| Q3 2020 | $12,000 | +9.1% | 1,404 | +25.8% | 0.00% | – |
| Q2 2020 | $11,000 | +120.0% | 1,116 | -1.2% | 0.00% | – |
| Q2 2019 | $5,000 | +150.0% | 1,129 | +329.3% | 0.00% | – |
| Q1 2019 | $2,000 | -66.7% | 263 | -84.3% | 0.00% | – |
| Q4 2018 | $6,000 | -62.5% | 1,676 | -21.6% | 0.00% | – |
| Q2 2018 | $16,000 | +100.0% | 2,137 | +107.5% | 0.00% | – |
| Q1 2018 | $8,000 | – | 1,030 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $76,809,898 | 25.63% |
| Lynx1 Capital Management LP | 2,404,614 | $27,532,830 | 18.21% |
| GREAT POINT PARTNERS LLC | 3,078,633 | $35,250,348 | 6.42% |
| Ghost Tree Capital, LLC | 664,132 | $7,604,311 | 2.50% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $34,186,918 | 2.27% |
| Paradigm Biocapital Advisors LP | 2,421,743 | $27,728,957 | 1.88% |
| COMMODORE CAPITAL LP | 1,325,000 | $15,171,250 | 1.77% |
| Nan Fung Group Holdings Ltd | 182,280 | $2,087,106 | 1.69% |
| Omega Fund Management, LLC | 153,700 | $1,759,865 | 1.62% |
| Octagon Capital Advisors LP | 750,000 | $8,587,500 | 1.32% |